Clinical Trial Update: CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial [EARLY_Phase 1]

View source ↗

Summary

This update describes an early-phase dose-escalation trial evaluating CART123 T cells in relapsed or refractory CD123+ hematologic malignancies, currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Myelodysplastic Syndrome
• Precursor B-cell Lymphoblastic Leukemia Lymphoma

Drugs mentioned

• CART123 T Cells

Snippet

Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic | Conditions: Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma | EARLY_Phase 1 | Status: RECRUITING